The independent medical news service

The rates of population-based screening and diagnosis of breast, cervical, and colorectal cancer in the USA in 2021 remained below those reported before the COVID-19 pandemic, researchers caution in JAMA Oncology.

A large US study has shown the feasibility of circulating tumor DNA analysis to detect KRAS G12C mutations in patients with solid tumors.

A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

US researchers have identified diverse molecular and histologic mechanisms of acquired resistance to KRAS G12C inhibitors in people with cancer.

Researchers have identified an association between socioeconomic deprivation and poor survival in people with cancer participating in clinical trials.